Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial – equivalent to almost $194,000 for its 14-day course – a higher level than had been ...
Sanofi has agreed a deal to buy US biopharma company Provention Bio for $2.9 billion, taking control of a recently-approved type 1 diabetes (T1D) prevention therapy Tzield that has been tipped as ...
Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback